The US laboratory Pfizer has raised its sales estimates for Comirnaty, the commercial name of its vaccine against Covid-19, so that it now expects to close 2021 with a turnover of this product of 36,000 million dollars (31,000 million euros), 7.5% more than previously expected.
Pfizer has attributed this increase in expectations to the fact that it has closed new vaccine supply deals since mid-July. The pharmaceutical company expects to distribute 2.3 billion doses of the vaccine this year, while production will be close to 3 billion doses.
The difference between the two data is due to the fact that a series of international shipments will take place in advance in December and will be recorded in the accounts for 2022. Likewise, the effect is also due, to a lesser extent, to the fact that doses will not be produced. They will be distributed before December 31, 2021.
In the third quarter of 2021, Pfizer posted sales of $ 12,977 million (€ 11,185 million) of its Covid-19 vaccine. In the whole of the first nine months of 2021, Comirnaty sales amounted to 24,277 million dollars (20,294 million euros).
“We are on track to achieve our goal of distributing at least 2 billion doses to low- and middle-income countries by the end of 2022,” said Pfizer President and CEO Albert Bourla.
The laboratory has reported these data taking advantage of the publication of its income statement referring to the third quarter of 2021. According to the document, in that period the company recorded an attributed net profit of 8,146 million dollars (7,021 million euros), which which is equivalent to multiplying by 5.5 the earnings of the same period of 2020.
Revenues between July and September reached 24,094 million (20,767 million euros), more than double than a year before, thanks largely to the injection against Covid-19.
By business segment, the vaccines division multiplied its revenue by 8.5, to 14,583 million (12,569 million euros), while the oncology branch stood at 3,085 million (2,659 million euros), 12% more, and that of products for hospitals increased 32%, to 2,367 million (2,040 million euros).
Sales in the internal medicine area grew 1%, to 2,097 million dollars (1,807 million euros), while the business of treatments for immunology and inflammations stood at 1,094 million (943 million euros), 7% less. Sales of products to treat rare diseases grew by 16%, to 869 million dollars (749 million euros).
Costs associated with sales increased almost fivefold, to 9,973 million (8,596 million euros), while selling, administrative and information expenses were 2,905 million dollars (2,504 million euros), 9% more . Research and development (R&D) increased 50% compared to the third quarter of 2020, to 3,447 million (2,971 million euros).
In the whole of the first nine months of 2021, Pfizer posted an attributable net profit of 18,586 million dollars (16,019 million euros), more than double that in the same period of the previous year. Between January and September, the turnover increased by 91%, up to 57,653 million (49,961 million euros).